AMDL Announces First Quarter 2008 Results Posting Sales of $3.58 Million

TUSTIN, Calif. (Map) - TUSTIN, Calif., May 15 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL) is a vertically integrated specialty pharmaceutical company headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin China. Through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), the Company engages in the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in the People's Republic of China. AMDL announced today that it had sales of approximately $3.58 million (unaudited) for the first quarter of 2008 compared to $1.4 million for the first quarter of 2007. It should be noted that first quarter sales are typically the lowest of the year due to Chinese holidays, which last for several weeks, and general industry trends. Please see AMDL's Form 10-Q for the period ended March 31, 2008 for more information.

    The First Quarter 2008 Financial Highlights (unaudited) include:
    --  Gross Profit.  AMDL gross profit for the three months ended March 31,
        2008 increased 144% to $1,771,016, compared to $726,869 for the same
        period in 2007.  JPI contributed $1,769,593 to the gross profit for
        the three months ended March 31, 2008, compared to $715,299 for the
        same period in 2007.
    --  Loss from Operations and Net Loss. AMDL consolidated net loss for the
        three months ended March 31, 2008 was $1,472,196 or ($0.10) per share,
        compared to a consolidated net loss of $1,385,406 or ($0.14) per share
        for the same period in 2007.

Gary Dreher, CEO of AMDL, stated that, "The continued improvements in AMDL's China operations, combined with other recently announced business opportunities create a financial platform for us to improve our sales and earnings profile during the remainder of FY2008 and beyond. This gives us greater confidence in AMDL's continued positive financial performance over the next year." AMDL's 2007 results as well as business improvement and opportunities referenced above include:

    --  FY2007 Sales of $15 Million and Gross Profits of $8.1 million;
    --  In-licensed MyGene's Human Papilloma Virus (HPV) Diagnostic Test;
    --  Signed LOI for the  purchase of a China based pharmaceutical
        distribution company with $28.55 million in revenue, approximately 10%
        NOI and 20-30% growth rate;
    --  Signed MOU with Hau Du Beauty Co., Ltd for its 200 stores to
        distribute Jade's Goodnak Product Line;
    --  AMDL launched a new updated website at http://www.amdl.com.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com. AMDL, together with Jade, engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products.

About Jade Pharmaceuticals Inc.: JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its Jade subsidiaries, currently holds licenses for 133 products that are manufactured as large volume injection fluids, tablets and other related products. It currently manufactures over 20 key generic, over-the-counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

Forward-looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

     Contact: AMDL, Inc.
     Mr. Paul Knopick
     AMDL Investor Relations
     Direct Line: 949.707.5365
     Voice Mail: 714.505.4460